Rapid Vaccine Manufacturing Facility: Emerging Pathogen Countermeasures Response. Initial Proof of Concept Stage
Abstract
Initial feasibility of using PCR-generated DNA vaccines (LEC) was completed as outlined in our proposal of July 21, OS. Specifically we demonstrated that (a) manufacture of milligram amounts of LEC DNA vaccine against H3N2 and H1N1 influenza strains was possible using microplate PCR technology; (b)resulting LEC DNA could be purified and formulated with the cationic lipid delivery system Vaxfectin and (c) vaccination of mice with Vaxfectin-formulated LEC vaccine resulted in protection against a lethal viral challenge. In addition, objectives outlined in our Expanded Aims proposal of Feb 21,06 were met. Specifically, we compared the performance of LEC vaccination to that of pDNA vaccination using the mouse influenza challenge model. These data indicate that Vaxfectin-formulated pDNA outperformed Vaxfectin-formulated LEC at doses between 0.4 and 0.08 ug. Protection data for pDNA vs. LEC at doses 2 ug or above were statistically indistinguishable. We also evaluated one potential scalable PCR device concept Heat transfer characteristics of materials and fluids were determined and PCR amplification was attempted at the 10 and 100 mL reaction volumes. Although DNA amplification was unsuccessful, causes for this outcome were identified and potential solutions have been proposed.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 15, 2007
- Accession Number
- ADA485782
Entities
People
- Adrian Vilalta
- Edward Domanico
- Jennifer Chaplin